NCT05642858 Text Education About Cardiovascular Health and HIV (TEACH-HIV)
| NCT ID | NCT05642858 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 260 participants |
| Start Date | 2023-03-12 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 260 participants in total. It began in 2023-03-12 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall objective is to evaluate the efficacy of educational text messages to reduce cardiovascular risk among persons living with HIV (PLWH).
Eligibility Criteria
Inclusion Criteria: * HIV positive * At least 40 years of age * English-speaking Exclusion Criteria: * Existing clinical atherosclerotic cardiovascular disease (ASCVD) * Pregnant * Unwilling/unable to provide informed consent * Does not own a smartphone
Contact & Investigator
Megan McLaughlin, MD, MPH
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05642858 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05642858 currently recruiting?
Yes, NCT05642858 is actively recruiting participants. Contact the research team at teachhiv@ucsf.edu for enrollment information.
Where is the NCT05642858 trial being conducted?
This trial is being conducted at San Francisco, United States, San Francisco, United States.
Who is sponsoring the NCT05642858 clinical trial?
NCT05642858 is sponsored by University of California, San Francisco. The principal investigator is Megan McLaughlin, MD, MPH at University of California, San Francisco. The trial plans to enroll 260 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.